

# Smart Contracts and Petri Dishes

Creating a Shared Technical Infrastructure Roadmap for DeSci

**Paul Kohlhaas**

Co-Founder, Molecule & VitaDAO

## Agenda.

1. Problems Definitions and Goals
2. What have we accomplished and learned
3. Where are we today
4. Hopes for the future
5. Workshop session and breakout groups



Problem Definition

“DeSci” has existed for around 1 year.



Problem Definition

crowd survey

# DECENTRALIZED SCIENCE LANDSCAPE

Distributed Fundraising • On-chain Publishing • IP-NFTs • Quadratic funding • Retroactive public goods funding

## DECENTRALIZED BIOTECH



## DECENTRALIZED FUNDING OF SCIENCE



## SCIENCE DAOs




## FOUNDATIONS & INSTITUTES




## PROTOCOLS & DATA




## SCIENTIFIC PUBLISHING



## SCIENCE NFTs



## COMMUNITIES & CHATS



CURATED BY:

@UltraRareBio -@jocelynnpearl & @danielyse\_

Designed by @katie\_koczera



Problem Definition

We have an opportunity today to define the roadmap for future builders and create an open collaborative technical infrastructure.





Problem Definition

DeSci will be most successful if enabled as  
interoperable permissionless lego blocks.





What lego blocks  
do we need?



For which types of  
DeSci applications?



# Science is full of problems.

## Funding

Funding is highly competitive and asymmetrically distributed. Most scientists would change topics and fields if funding was not a concern. We spend too much time applying for it.

## Replication

Much of science is not reproducible. We work in silos and often fail to report negative results. Much of science is built on invalid data. Incentives are perverse.

## Competition

Science has become hyper-competitive, creating perverse incentives. The life of a young academic is incredibly stressful, publish or perish, and less than 2% of NIH funding to under 35 y/o's.

## Comms

Science is inaccessible. Much of the important scientific literature lives behind paywalls, out of the reach of the population. Dissemination, peer-review, and access are broken.

# Some problems stem from centralizing authorities.

## Funding

Funding is largely centralized by governments with tax-dollar funding, yet the public is largely excluded from the decision-making process around what is funded.

## Replication

Centralized scientific communities, which use similar methods and involve shared authors who contribute to many articles, propagate less replicable claims than decentralized communities


## Competition

Competition for publishing, tenure track positions, and unilateral career movement is predicated on engagement with a few centralized and powerful agencies and universities.

## Comms

Centralized authorities control access to information and determine the rules of how we communicate science and who reads them. These authorities have asymmetrical power.

What if science  
is decentralized?



# Why is decentralization important?

Centralized institutions have played an important role in the facilitation of science, but can sometimes fall short.

---

Users participate in a trustless system

---

Lowers risk of systemic failure

---

Censorship resistance fosters an open culture.

---

Enables global collaboration

---

# Why, what, and how DeSci?

01

## Why

To build on the open science movement, make science more collaborative, and make science accessible to everyone.

02

## What

A global, open alternative to the current scientific system that anyone can participate in.

03

## How

Technology that enables scientists to raise funding, run experiments, share data, distribute insights, and more, openly.



# DeSci Verticals

Areas that DeSci is currently targeting and attempting to disrupt.

---

## 01 Funding of Data, IP and Impact

Faster, more democratic funding mechanisms that enable communities to form and govern impact and IP.

---

## 02 Publishing

Transparent, open access publishing with aligned incentives. Peer review is incentivized.

---

## 03 DAOs & Research Governance

DAOs present new ways of organising researcher or patient involvement and clinical trials.


---

## 04 Identity and Reputation

Individuals to prove their experience and credentials linked to their Ethereum address for example.

---

Of these verticals,  
funding and IP  
are seeing the  
most progress.



# Funding + IP

The current standard model for funding science is that individuals or groups of scientists make written applications to a funding agency, or form a company to raise VC.

---

## 01 Retroactive Public Goods Funding

Projects receive funding for achieving certain goals, created by the public.

---

## 02 Quadratic Funding

A fairer, more democratic and balanced way to allocate funding to projects

---

## 03 DAOs/Tokenized Incentive Structures

Communities vote to decide how funding is allocated. They govern over projects.



---

## 04 IP-NFTs

Ownership in research related IP as an incentive for funding and collaboration.

---


# Example: Innovation & Biotech Research Today



# IP and Patents are Legacy Legal Physical Assets.

1. Bureaucratic and outdated IP systems make IP hard to transact
2. Often too expensive to structure and negotiate early stage IP
3. Fuels the Valley of Death as IP gets shelved due to inefficiency

Data and Software is Virtual.





USPTO PATENT FULL-TEXT AND IMAGE DATABASE

[Home](#) [Quick](#) [Advanced](#) [Pat Num](#) [Help](#)

[Next List](#) [Bottom](#) [View Cart](#)

Results of Search in US Patent Collection db for:  
psilocybin: 921 patents.  
Hits 1 through 50 out of 921

Jump To

PAT. NO.	Title
11 441.164	<a href="#">Biosynthetic production of psilocybin and related intermediates in recombinant organisms</a>
12 440.879	<a href="#">Methods of treating mood disorders</a>
13 432.772	<a href="#">Systems and methods for replacing signal artifacts in a glucose sensor data stream</a>
14 422.604	<a href="#">Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders</a>
15 426.400	<a href="#">Methods of increasing satellite cell proliferation with vorinostat or bosutinib</a>
16 426.367	<a href="#">Methods of treating substance abuse</a>
17 420.967	<a href="#">Modified carbazoles as therapeutic agents</a>
18 419.280	<a href="#">Methods of crossbreeding fruit enzymes</a>
19 414.423	<a href="#">Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders</a>
20 412.966	<a href="#">Transcutaneous analyte sensor systems and methods</a>
21 406.619	<a href="#">Injectable formulations</a>
22 400.106	<a href="#">Methods for inhibiting microbe growth</a>
23 399.745	<a href="#">Dual electrode system for a continuous analyte sensor</a>
24 399.742	<a href="#">Systems and methods for a continuous monitoring of analyte values</a>
25 395.824	<a href="#">5-HTT sub C2 receptor agonists and compositions and methods of use</a>
26 395.631	<a href="#">Transcutaneous analyte sensors, applicators therefor, and associated methods</a>


### Modified carbazoles as therapeutic agents

This disclosure relates to compounds that target microtubules, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases. More particularly, this disclosure relates to pharmaceutical compositions thereof, methods of targeting microtubules with these compounds, and methods of treating diseases affected by microtubule disruption.

Prior Publication Data		
Document Identifier		Publication Date
US 20210094949 A1		Apr 1, 2021
Related U.S. Patent Documents		
Application Number	Filing Date	Patent Number
62683953	Jun 12, 2018	
62714436	Aug 3, 2018	


# IP monopolies kill innovation – and lead to high drug prices

- Restricts scientific collaboration and "discoverability of IP" as organisations work in siloes.
- Limits open science, creates reproducibility crisis as negative data is buried.
- Rather than the best science, revenue-drivers dominate medicine.




What could a  
different system  
look like?

Towards an open  
market for IP



Most of the world's  
potential scientific talent  
remains untapped.


Let's enable a Creator  
Economy for Scientists...





# Molecule's Mission: Realigning Incentives via Decentralised Biotech


## Towards an open transparent market for research funding






How do we bring  
legal IP and Data  
into Web3?

A DeSci Lego  
Block: IP-NFTs




# Anatomy of IP-NFTs

1. **Legal** - legal contracts & license tied to real-world research or data
2. **Storage** - decentralised permanent data storage, public and private data repos
3. **Transactability** - seamless transfer of IP
4. **Discoverability** - via public metadata
5. **Programmability of IP**
  - a. **Governance**
  - b. **Fractionalisation (FRENS framework)**
  - c. **Programmatic royalties**
  - d. **Pay-for-success models**



# Anatomy of IP-NFTs



# IP-NFTs are composable Web3 building blocks



1. Can be transacted like NFTs and applied in funding
2. DAOs can now build portfolios of research (Bio DAOs)
3. NFTs can be fractionalised and act as DeFi lego blocks
4. Data access can be granted via multi-sigs

Only scratching the surface...

# DeSci Web3 Lego Blocks

---

01 Transaction Layers

---

02 Data Storage Layers


---

03 Compute & Execution Layers

---

04 Identity Layers

---





## Workshop Goals

The goal of this workshop will be **to explore how decentralized science can improve the process of funding, doing, and disseminating science through the use of decentralized systems.**

Groups can break into the following verticals to explore the problem space and brainstorm solutions:

1. Funding and IP
2. Data and Reproducibility
3. Publishing
4. Identity and Reputation

# Workshop Flow

Setting the  
Scene (20min)

Breakout 1  
(40min)

Breakout Pitches  
(10min)

Discussion  
(40min)

Call to Action  
(10min)



# Workshop and Breakouts



# DeSci Verticals

Areas that DeSci is currently targeting and attempting to disrupt.

---

## 01 Funding of Data, IP and Impact

Faster, more democratic funding mechanisms that enable communities to form and govern impact and IP.

---

## 02 Publishing

Transparent, open access publishing with aligned incentives. Peer review is incentivized.

---

## 03 DAOs & Research Governance


DAOs present new ways of organising researcher or patient involvement and clinical trials.

---

## 04 Identity and Reputation

Individuals to prove their experience and credentials linked to their Ethereum address for example.

---



# Thank you!

**Paul Kohls**

Co-Founder, Molecule & VitaDAO

[paul@molecule.to](mailto:paul@molecule.to)



[@paulkhl](https://twitter.com/paulkhl)